Pharminent

New Infographic: A Response to “A Better Deal” on Drug Pricing

The United States is the global leader in biomedical innovation, discovering more new cures than … http://www.biotech-now.org/health/2017/09/new-infographic-a-response-to-a-better-deal-on-drug-pricing

Filed under: Pricing

On Drug Pricing: FDA Backs Up Its Calls for Increased Competition

FDA Commissioner Scott Gottlieb has been very public in expressing his desire to provide increased competition and greater choice to American consumers in a bid to drive down prices of prescription medicines. Recently, the agency he oversees took some unusual steps to back up those statements with action. Last week, the FDA approved the use […] http://www.xconomy.com/san-diego/2017/08/21/on-drug-pricing-fda-backs-up-its-calls-for-increased-competition/

Filed under: Pricing

Perspectives: More Transparent Pricing System Would Help Untangle Confusion Around High Costs

Read recent commentaries about drug-cost issues. http://khn.org/morning-breakout/perspectives-more-transparent-pricing-system-would-help-untangle-confusion-around-high-costs/

Filed under: Pricing

EU tests limits of drug pricing freedom in landmark probe

BRUSSELS/LONDON (Reuters) – The first ever EU antitrust probe into excessive drug pricing is taking the European pharmaceuticals industry into uncharted territory, unnerving some companies and lawyers worried about the reach of market intervention.

http://www.reuters.com/article/us-pharmaceuticals-eu-pricing-analysis-idUSKBN19H1IY

Filed under: Pricing

Taking office, Gottlieb keeps drug pricing front and center

The newly sworn-in FDA Commissioner told agency staff he hopes to speed lower cost generics to market and increase competition, particularly for complex drug products and biologics. http://www.biopharmadive.com/news/gottlieb-fda-drug-prices-generics-lower-cost/442824/

Filed under: Pricing

Sanofi pegs U.S. drug price rises to below healthcare inflation

(Reuters) – French drugmaker Sanofi has pledged to peg U.S. drug price rises to below healthcare inflation in a move that limits increases for any product this year to 5.4 percent, unless there are exceptional circumstances.

http://www.reuters.com/article/us-sanofi-usa-idUSKBN1851HA

Filed under: Pricing

Pricing row shines spotlight on US pharmacy benefit managers

Anthem dispute with Express Scripts shifts focus in battle over high drug prices https://www.ft.com/content/b6c90a12-2ebf-11e7-9555-23ef563ecf9a

Filed under: Pricing

Medicare Drug Price Debate Puts Regeneron At Risk

https://seekingalpha.com/article/4064085-medicare-drug-price-debate-puts-regeneron-risk

Filed under: Pricing

Lilly offers up drug pricing details amid ongoing scrutiny of industry

Following criticism over the cost of its insulin drugs, the company gave a glimpse into its pricing decisions in an annual report. http://www.biopharmadive.com/news/Eli-lilly-pricing-report/438474/

Filed under: Pricing

J&J latest pharma firm to volunteer pricing data

Johnson & Johnson released its pricing data, as promised, in February and it has simply revealed that its average price increases have been below the 10% mark annually for the last five years. It follows a similar path trodden by MSD, known as Merck in North America, in the release of a brief table of price increases but levelled against the ‘Net Price Change’ that factors in rebates and reimbursements.
read more http://www.pharmafile.com/news/513441/jj-latest-pharma-firm-volunteer-pricing-data

Filed under: Pricing

Physicians calls for value-based drug pricing

The largest group of U.S. physicians said drug pricing needs to align with the broader healthcare industry’s drive for value. http://www.mmm-online.com/physicians-calls-for-value-based-drug-pricing/article/573621/

Filed under: Pricing

Biogen’s Tecfidera, Amgen’s Enbrel tell a tale of pricing power and weakness

http://www.fiercepharma.com/pharma/amgen-bids-farewell-to-enbrel-price-hikes-and-big-sales-boosts-they-brought

Filed under: Pricing

How Congress Can Make Drug Pricing More Rational

The public reproach over the price of Mylan’s lifesaving drug EpiPen is the latest imbroglio in a much broader debate over drug costs. At issue is the rising list price on drugs. But as Mylan argued, these high reported prices often bear little relation to the real price actually paid, after rebates and discounts, by most health plans. http://www.forbes.com/sites/scottgottlieb/2016/09/12/how-congress-can-make-drug-pricing-more-rational/

Filed under: Pricing

Novartis sees more restrictive drug pricing to come in US

Speaking to the Financial Times, Joe Jimenez said drug pricing would become more difficult regardless of who wins the U.S. presidential election this fall.  http://www.biopharmadive.com/news/novartis-ceo-sees-more-restrictive-drug-pricing-to-come-in-us/423046/

Filed under: Pricing

Industry weighs radical shake-up of European drug pricing

[Reuters] – The pharmaceutical industry is considering a radical shift in the way it prices drugs in Europe so companies are rewarded for the clinical benefit of treatments rather than the number of pills sold, according to an internal report.http://finance.yahoo.com/news/industry-weighs-radical-shake-european-090100334.html

Filed under: Pricing

PCMA “PBM Policy Forum” Tackles Prescription Drug Pricing Debate

WASHINGTON, April 11, 2016 /PRNewswire-USNewswire/ — Today, the Pharmaceutical Care Management Association (PCMA) holds its annual “PBM Policy Forum" at the Newseum in Washington, D.C. The event will focus on market-based solutions to lower the cost of prescription drugs, such… http://www.prnewswire.com/news-releases/pcma-pbm-policy-forum-tackles-prescription-drug-pricing-debate-300249237.html

Filed under: Pricing

Sanofi EVP Weighs In On The Politics Of Drug Pricing

http://www.lifescienceleader.com/doc/sanofi-evp-weighs-in-on-the-politics-of-drug-pricing-0002

Filed under: Pricing

Walgreens CEO hops on the pricing critic train, says consumer Rx should be cheaper

Stefano Pessina, whose retail pharmacy giant recently struck a 20-year distribution deal with the embattled Valeant, thinks consumers should be further shielded from pricing pain.  http://www.biopharmadive.com/news/walgreens-ceo-hops-on-the-pricing-critic-train-says-consumer-rx-should-be/412583/

Filed under: Pricing

Drug Price Policy Can’t Discourage R&D: Biogen CEO

http://www.bloomberg.com/news/videos/2016-01-12/drug-price-policy-can-t-discourage-r-d-biogen-ceo

Filed under: Pricing

CEOs: What’s missing in the drug pricing debate

http://www.cnbc.com/2016/01/11/ceos-whats-missing-in-the-drug-pricing-debate.html

Filed under: Pricing

Categories